Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294331 · ClinicalTrials.gov registry record
Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 1,900
- Enrollment target
NCT02294331: Completed study, sponsored by Medtronic.
NCT02294331 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 1,900 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02294331 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 1,900 participants
- Enrollment target
Study Summary
Lead survivability will be summarized.
Primary Outcome
Survival analysis will be used to analyze the lead. Lead status will be reported as a function of time post-implant for all leads in the study. Lead related complications include but are not limited to: failure to capture, abnormal sensing, threshold rise, abnormal impedance, insulation breach, conductor fracture, extracardiac stimulation, lead dislodgement, cardiac perforation, structural lead failure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2014-08 |
| Est. Completion | 2021-07-31 |
What the finished NCT02294331 record still lists
NCT02294331 is an observational study that tracks outcomes without assigning an intervention. Its 1,900 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02294331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02294331 about?
NCT02294331 is a clinical study titled "Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study". Lead survivability will be summarized.
What is the current status of trial NCT02294331?
This trial is currently completed. The enrollment target is 1,900 participants. The study started on 2014-08. Estimated completion is 2021-07-31.
Who is sponsoring clinical trial NCT02294331?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia